At issue is mifepristone, part of a two-drug protocol used in medication abortions, the most common form of the procedure today. Under current Food and Drug Administration protocols, the drug can. -March 26, 2024 at 06:10 am EDT
- MarketScreener
North American Morning Briefing: Markets Steady -2- morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Orgenesis Inc (NASDAQ:ORGS) has entered into a definitive agreement with MM OS Holdings, an affiliate of Metalmark Capital Partners, to acquire its approximate 25% stake in Octomera. Octomera is Orgenesis’s cell processing services subsidiary, and the transaction allows the company to have 100% ownership of this business unit. In exchange, Metalmark will receive a royalty of 5% of the net revenue of Octomera’s cell processing services for the three calendar years 2025-2027, along with a portion
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.